REVB
Revelation Biosciences, Inc.Company with tickers: REVB, REVBW
CIK
1810560
CUSIP
76135L804
Shares Outstanding
3,908,420
13F Activity (30d)
9 filings
9 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $3,092,500 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Research & Development | $1,376,861 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Operating Income | $-3,092,500 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Net Income | $-3,009,051 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| EPS (Basic) | $-2.71 | USD/shares | 2026-03-31 | 10-Q | 2026-05-07 |
| EPS (Diluted) | $-2.71 | USD/shares | 2026-03-31 | 10-Q | 2026-05-07 |